Hematological parameters as predictors of immune-related adverse events: risk factor analysis in non-small cell lung cancer patients undergoing immunotherapy
Pretreatment assessment of ANC, LYM, NLR, PLR, SII, AAPR, and AFR provides valuable predictive utility for irAEs risk in NSCLC patients undergoing immunotherapy. Integrating these biomarkers into clinical practice may enhance risk stratification and guide personalized treatment strategies to improve safety and therapeutic outcomes.
Authors
- Yong Jia
Institutions
- Baoji City Central Hospital (CN)
Publication Details
- Journal
- American Journal of Translational Research
- Published
- 2025-01-01
- DOI
- https://doi.org/10.62347/euhl7337
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05